Incannex Healthcare has received ethics approval to test the bioavailability of its cannabinoid combination drug in the treatment of obstructive sleep apnoea.
A clinical trial for IHL-42X – the company’s proprietary product which contains dronabinol and acetazolamide – will assess the pharmacokinetics and tolerability compared to drugs listed by the US Food and Drug Administration.
Join the Cannabiz revolution
Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?
This article is included with our Premium subscription.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Vel turpis nunc eget lorem dolor sed. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Nisl nunc mi ipsum faucibus vitae.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
